Antivirus/immunomodulatory Therapy In HBeAg Positive And Treatment-naive Patients With Chronic Hepatitis B

BackgroundThere are about 350 million chronic hepatitis B patients in the world, in which China accounts for a third, about 93 million, infection rate was 7.18%.15-25% of CHB patients develops into liver failure, liver cirrhosis or hepatocellular carcinoma (HCC), about 1 million people die each year from end-stage disease caused by HBV infection.AimTo create a new solution, that can improve the negative rate of hepatitis B surface antigen in the HBeAg positive untreated chronic hepatitis b patients. Simultaneously, verify and evaluate the curative effect of CHB.MethodsDivide 360 CHB patients into four group (Ⅰ:IFN-α; Ⅱ:IFN-α+ADV; Ⅲ:IFN-α+ADV+GM-CSF; Ⅳ:IFNα+ADV+GM-CSF+Vaccine). Collect and statistical analyze the related data.Results1. the negative rate of HBsAg:Ⅰ:0%;Ⅱ:3.4%;Ⅲ:4.7%;Ⅳ:9.0%. Ⅰ to Ⅱ、Ⅲ or Ⅳ:p<0.05,Ⅱ to Ⅳ:p<0.05, others:p>0.05; 2. the negative rate of HBeAg:Ⅰ: 14.4%; Ⅱ:21.3%; Ⅲ:27.1%;Ⅳ:36.0%. Ⅰ to Ⅲ or Ⅳ:p<0.05, Ⅱ to IV:p<0.05, others:p>0.05; 3. Sustained Biological Response:Ⅰ:53.3%; Ⅱ:74.7%; E1:77.6%; IV:80.0%, Ⅰ to Ⅱ、Ⅲ or Ⅳ:p<0.05, others:p>0.05; 4. biochemical response:I: 66.7%; Ⅱ:88.8%; Ⅲ:90.6%; Ⅳ:91.0%, Ⅰ to Ⅱ Ⅲ or IV:p<0.05, others:p>0.05; 5. Histological response:I:12/22(54.5%); II:18/24(75.0%); Ⅲ:20/25(80.0%); Ⅳ:14/22 (63.6%), p>0.05.ConclusionThe research proves that:the new solution can improve the negative rate of HBsAg to the HBeAg positive untreated chronic hepatitis b patients, and it only need RMB 12000 for the 48 weeks of treatment, it is advantageous to popularize the research results in China.